FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial (Q34663697)
Jump to navigation
Jump to search
scientific article
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial |
scientific article |
Statements
1 reference
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial (English)
1 reference
Ursula Vehling-Kaiser
1 reference
Ludwig Fischer von Weikersthal
1 reference
Tobias Heintges
1 reference
Volker Heinemann
1 reference
Thomas Decker
1 reference
Alexander Kiani
1 reference
Salah-Eddin Al-Batran
1 reference
Christian Lerchenmüller
1 reference
Christoph Kahl
1 reference
Gernot Seipelt
1 reference
Frank Kullmann
1 reference
Martina Stauch
1 reference
Werner Scheithauer
1 reference
Jörg Hielscher
1 reference
Michael Scholz
1 reference
Sebastian Müller
1 reference
Hartmut Link
1 reference
Norbert Niederle
1 reference
Andreas Rost
1 reference
Heinz-Gert Höffkes
1 reference
Markus Moehler
1 reference
Reinhard U Lindig
1 reference
Dominik P Modest
1 reference
Lisa Rossius
1 reference
Thomas Kirchner
1 reference
Andreas Jung
1 reference
Sebastian Stintzing
1 reference
31 July 2014
1 reference
1 reference
15
1 reference
10
1 reference
1065-1075
1 reference
Identifiers
1 reference
1 reference